Not found

Mauro Ferrari, PhD

Ernest Cockrell, Jr. Presidential Distinguished Chair, President & CEO, Research Institute
Director & Professor of Nanomedicine, Institute for Academic Medicine
Executive Vice President, Houston Methodist
Senior Associate Dean and Professor of Medicine, Weill Cornell Medical College


Research Lab


mferrari@houstonmethodist.org
Biography

Mauro Ferrari, PhD, is the Executive Vice President of Houston Methodist and the President and CEO of the Houston Methodist Research Institute where he is the Ernest Cockrell Jr. Presidential Distinguished Chair. As the Director of the Houston Methodist Institute for Academic Medicine, Ferrari oversees all research and education programs at Houston Methodist, over 1,200 research employees and credentialed clinicians executing more than 800 clinical protocols. He also serves as the Senior Associate Dean of the Weill Cornell Medical College, the primary academic affiliate of Houston Methodist and holds Adjunct and Honorary Professorships at many universities around the world.

Ferrari is the founder of biomedical nano/micro-technology, especially in their applications to drug delivery, cell transplantation, implantable bioreactors, and other innovative therapeutic modalities. Dr. Ferrari served as special expert on nanotechnology at the National Cancer Institute in 2003-2005, providing leadership for the formulation, refinement, and approval of the NCI's Alliance for Nanotechnology in Cancer, currently the world's largest program in medical nanotechnology.

He has to his credit more than 350 publications, including seven books and is the inventor of 30 issued patents in the US and Europe. Throughout his academic career, he has supervised trainees and students who have gone on to senior faculty positions at premier universities like Oxford, Massachusetts Institute of Technology (MIT), University of California Berkeley, University of California San Francisco, Duke University, University of Washington, and Ohio State University. Dr. Ferrari's degrees are in Mathematics (Padova, Italy), and Mechanical Engineering (M.S., & Ph.D., U.C. Berkeley).

His seminal contributions to the field of biomedical nanotechnology have been recognized through numerous awards and accolades, including: Founders Award - Controlled Release Society, the Wallace H. Coulter Award for Biomedical Innovation and Entrepreneurship, the ETH Zürich Stodola Medal, Blaise Pascal Medal in Biomedical Engineering - European Academy of Sciences, and the Shannon Director's Award of the National Institutes of Health. Dr. Ferrari is a Fellow of the American Society of Mechanical Engineers, American Academy for the Advancement of Science and American Institute for Medical and Biological Engineering. He also holds honorary doctorates in Electrical Engineering and Biotechnology from the University of Palermo and the University of Naples “Federico II”, respectively.

His career research and development portfolio totals over $50 million, including support from the NCI, NIH, DoD, NASA, NSF, DARPA, DoE, the state of Texas, the state of Ohio, the Ohio State University, and several private enterprises. He began his academic career at the University of California, Berkeley, where he tenured in Material Science, Civil Engineering, and Bioengineering. Upon recruitment to the Ohio State University, he served as the Edgar Hendrickson Professor of Biomedical Engineering, Professor of Internal Medicine, Mechanical Engineering and Materials Science. He was also the Associate Vice President, Health Sciences Technology and Commercialization, Associate Director of the Dorothy M. Davis Heart and Lung Research Institute and Director of the Biomedical Engineering Center. Upon recruitment to Houston, he served as professor and chair of the nanomedicine department at the University of Texas Health Science Center.

Description of Research

Nanomedicine for oncology, traumatic injury, cardiovascular disease, infectious pathologies, and diabetes
Nanofluidics
Biomedical Microtechnology (BioMEMS)
Drug delivery
Proteomics and peptidomics for early detection and therapeutic monitoring
Cell transplantation, regenerative medicine, and tissue engineering
Biosensors and bioseparation technology
Multiscale discrete/continuum mechanics and biomechanics
Bioethics

Areas Of Expertise

Nanomedicine Nanofluidics Cancer Drug delivery Biomedical microtechnology (BioMEMS)
Education & Training

Dottore, Universita' di Padova
PhD, University of California Berkeley
Publications

Transport Barriers and Oncophysics in Cancer Treatment
Nizzero, S, Ziemys, A & Ferrari, M 2018, Trends in Cancer. DOI: 10.1016/j.trecan.2018.02.008

Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Zhu, M, Ding, X, Zhao, R, Liu, X, Shen, H, Cai, C, Ferrari, M, Wang, HY & Wang, RF 2018, Journal of Controlled Release, vol 272, pp. 72-82. DOI: 10.1016/j.jconrel.2018.01.004

Implementation of Transitional Strategic Plan at an Academic Medical Center
MacCorkle-Chosnek, R, Ferrari, M & Bass, BL 2018, Academic Medicine.

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, pp. 1700530-n/a. DOI: 10.1002/advs.201700530

Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration
Wu, S, Zhang, A, Li, S, Chatterjee, S, Qi, R, Segura-Ibarra, V, Ferrari, M, Gupte, A, Blanco, E & Hamilton, DJ 2018, Advanced Science, pp. 1700530-n/a. DOI: 10.1002/advs.201700530

A novel DNA aptamer for dual targeting of polymorphonuclear myeloid-derived suppressor cells and tumor cells
Liu, H, Mai, J, Shen, J, Wolfram, J, Li, Z, Zhang, G, Xu, R, Li, Y, Mu, C, Zu, Y, Li, X, Lokesh, GL, Thiviyanathan, V, Volk, DE, Gorenstein, DG, Ferrari, M, Hu, Z & Shen, H 2018, Theranostics, vol 8, no. 1, pp. 31-44. DOI: 10.7150/thno.21342

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy
Marcazzan, S, Varoni, EM, Blanco, E, Lodi, G & Ferrari, M 2018, Oral Oncology, vol 76, pp. 1-7. DOI: 10.1016/j.oraloncology.2017.11.014

Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity
Wu, X, Hu, Z, Nizzero, S, Zhang, G, Ramirez, MR, Shi, C, Zhou, J, Ferrari, M & Shen, H 2017, Journal of Controlled Release, vol 268, pp. 92-101. DOI: 10.1016/j.jconrel.2017.10.012

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
Shen, H, Xia, X & Ferrari, M 2017, , Patent No. AU2016243027, IPC No. A61K 39/ 12 A I.

A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery
Wolfram, J, Nizzero, S, Liu, H, Li, F, Zhang, G, Li, Z, Shen, H, Blanco, E & Ferrari, M 2017, Scientific Reports, vol 7, no. 1, pp. 13738. DOI: 10.1038/s41598-017-14221-2

Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells
Shen, H, Sun, T, Hoang, HH, Burchfield, JS, Hamilton, GF, Mittendorf, EA & Ferrari, M 2017, Seminars in Immunology. DOI: 10.1016/j.smim.2017.09.002

Contribution of Kupffer cells to liposome accumulation in the liver
Samuelsson, E, Shen, H, Blanco, E, Ferrari, M & Wolfram, J 2017, Colloids and Surfaces B: Biointerfaces, vol 158, pp. 356-362. DOI: 10.1016/j.colsurfb.2017.07.014

Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention
Segura-Ibarra, V, Cara, FE, Wu, S, Iruegas-Nunez, DA, Wang, S, Ferrari, M, Ziemys, A, Valderrabano, M & Blanco, E 2017, Journal of Controlled Release, vol 262, pp. 18-27. DOI: 10.1016/j.jconrel.2017.07.012

Tumor progression effects on drug vector access to tumor-associated capillary bed
Kiseliovas, V, Milosevic, M, Kojic, M, Mazutis, L, Kai, M, Liu, YT, Yokoi, K, Ferrari, M & Ziemys, A 2017, Journal of Controlled Release, vol 261, pp. 216-222. DOI: 10.1016/j.jconrel.2017.05.031

Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma
Borsoi, C, Leonard, F, Lee, Y, Zaid, M, Elganainy, D, Alexander, JF, Kai, M, Liu, YT, Kang, Y, Liu, X, Koay, EJ, Ferrari, M, Godin, B & Yokoi, K 2017, Cancer Letters, vol 403, pp. 296-304. DOI: 10.1016/j.canlet.2017.06.026

A composite smeared finite element for mass transport in capillary systems and biological tissue
Kojic, M, Milosevic, M, Simic, V, Koay, EJ, Fleming, JB, Nizzero, S, Kojic, N, Ziemys, A & Ferrari, M 2017, Computer Methods in Applied Mechanics and Engineering, vol 324, pp. 413-437. DOI: 10.1016/j.cma.2017.06.019

Evolution of the scientific literature on drug delivery: A 1974–2015 bibliometric study
Robert, C, Wilson, CS, Venuta, A, Ferrari, M & Arreto, CD 2017, Journal of Controlled Release, vol 260, pp. 226-233. DOI: 10.1016/j.jconrel.2017.06.012

Exosomes as Reconfigurable Therapeutic Systems
Conlan, RS, Pisano, S, Oliveira, MI, Ferrari, M & Mendes Pinto, I 2017, Trends in Molecular Medicine. DOI: 10.1016/j.molmed.2017.05.003

Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity
Ban, Y, Mai, J, Li, X, Mitchell-Flack, M, Zhang, T, Zhang, L, Chouchane, L, Ferrari, M, Shen, H & Ma, X 2017, Cancer Research, vol 77, no. 11, pp. 2857-2868. DOI: 10.1158/0008-5472.CAN-16-2913

Highly efficient genome editing of human hematopoietic stem cells via a nano-silicon-blade delivery approach
Ma, Y, Han, X, Quintana Bustamante, O, Bessa De Castro, R, Zhang, K, Zhang, P, Li, Y, Liu, Z, Liu, X, Ferrari, M, Hu, Z, Carlos Segovia, J & Qin, L 2017, Integrative Biology (United Kingdom), vol 9, no. 6, pp. 548-554. DOI: 10.1039/c7ib00060j